Astrazeneca CEO 'delighted' with strategic progress
18th Nov 2014 07:11
Pharmaceutical group Astrazeneca has hailed the progress it has made on its strategy to deliver "sustainable growth and value through innovation". In a presentation to investors and analysts in London on Tuesday, the company is expected to update on its growth prospects and pipeline, saying it remai
Read moreThursday broker round-up.-Update
13th Nov 2014 10:21
AstraZeneca: JP Morgan raises target price from 3700p to 4100p, keeping its underweight rating. AVEVA Group: Barclays upgrades to overweight. Bellway: Credit Suisse raises target price from 1876p to 1905p and keeps a neutral rating. Bow Leven: Barclays shifts target price from 45p to 50p and retai
Read moreAstrazeneca sees success with psoriasis treatment
12th Nov 2014 07:13
Astrazeneca has reported positive results from the phase three trial of its psoriasis treatment, broadalumab. The drugs maker said the treatment, when tested on 1,800 patients with moderate-to-severe plaque psoriasis, was more successful in achieving total clearance compared to both its Stelara drug
Read moreFriday broker round-up UPDATE
7th Nov 2014 09:44
AstraZeneca: Deutsche Bank increases target price from 4100p to 4350p and reiterates its hold recommendation. AVEVA: Societe Generale reduces target price from 2250p to 2000p, while keeping its buy recommendation. Big Yellow Group: Citi raises target price from 470p to 540p and maintains its neutra
Read moreFriday tips round-up: Tate & Lyle, AstraZeneca
7th Nov 2014 08:44
Tate & Lyle has had a very difficult year with the two profit warnings. The reasons behind the downgrades are varied, ranging from cold weather in the US to a fire at the Singapore factory where its sweetener Sucralose is manufactured. In aggregate all of those negatives knocked £41m out of the comp
Read moreBroker tips: WM Morrison, Astrazeneca, M&S, Shanks
6th Nov 2014 13:00
Shore Capital has retained a 'hold' rating for supermarket group Wm Morrison after a mixed set of third-quarter results, saying that it is "critical" that trading improves over the pivotal Christmas period. "It is essential that the group trades much more robustly in the current quarter and then dis
Read moreAnalyst consensus points to a 'hold' at Astrazeneca, says Hargreaves Lansdown
6th Nov 2014 12:37
Upgrades to full-year guidance at pharmaceutical firm Astrazeneca may have reassured investors, but the average analyst still remains on the fence, according to Hargreaves Lansdown Stockbrokers. It said that the analyst consensus opinion is currently pointing to a 'hold', with the share price having
Read moreAstrazeneca ups 2014 revenue and profit guidance
6th Nov 2014 07:39
Drug group Astrazeneca has increased its full-year revenue and earnings guidance after good performances by its flagship drugs in the third quarter. The group said 2014 annual revenue was now expected to increase in low single digits at constant exchange rates rather than its previous guidance for r
Read moreAstrazeneca buys tumour tech firm Definiens for $150m
4th Nov 2014 07:19
Drug giant Astrazeneca's research and development arm, Medimmune, has agreed to purchase imaging and data analysis technology company Definiens. Medimmune will pay $150m, together with additional pre-determined milestone payments. Definiens has developed a technology called tissue phenomics, which
Read moreAstrazeneca gains rights to Almirall respiratory franchise
3rd Nov 2014 07:10
Astrazeneca has gained the development and commercialisation rights to Almirall's respiratory franchise, giving it access to all on-market revenues, the drugs maker said. The group will pay an initial $875m, plus up to a further $1.22bn in development, launch and sales-related milestones. The deal,
Read moreLondon pre-open: Chinese PMI data to drag FTSE lower early on
2nd Nov 2014 17:33
Tracking a weaker session in Asia overnight, UK stocks are expected to begin a macro-focused week with small gains. City sources predict the FTSE 100 will open around nine points lower than Friday's close of 6,546.47. "As we approach a major week in the markets in terms of economic events, we are l
Read moreLondon open: Miners drag UK stocks lower, but Barclays gains
30th Oct 2014 08:34
London's stock exchange opened more or less flat on Thursday as heavy falls from mining stocks and BT offset gains from Barclays and St James's Place. The FTSE 100 was trading 0.1% lower at 6,449 in early deals. The subdued start follows a weak performance on Wall Street overnight as investors reac
Read moreAstrazeneca type 2 diabetes drug approved for use by US FDA
30th Oct 2014 07:48
Astrazeneca's Xigduo XR type 2 diabetes treatment has been approved for use in adults by the US Food and Drug Administration (FDA). The drug, which is already approved in Australia, is taken as a once-daily tablet that removes glucose from the body via the kidneys. "The addition of Xigduo XR to our
Read moreAstrazeneca's Olaparib treatment given thumbs up by European committee
24th Oct 2014 12:48
Friday brought good news for Astrazeneca shareholders after its Olaparib treatment was recommended for marketing authorisation by a European Medicines Agency (EMA) committee. The committee for Medicinal Products for Human Use (CHMP) gave the drug the thumbs-up for the treatment of women with BRCA-mu
Read moreMonday broker round-up UPDATE
13th Oct 2014 09:32
Amino Technologies: Northland Capital upgrades to buy with a target price of 100p. Anglo American: Canaccord Genuity initiates with a target price of 1720p and a buy recommendation. Credit Suisse upgrades to outperform with a target price of 1800p. Associated British Foods: Societe Generale upgrade
Read more